Bezlotoxumab: A Novel Drug for Reduction of Recurrent Clostridium difficile Infections Whitaker, Andrea; Cosimi, Reese A.; Reveles, Kelly R.; More Whitaker, Andrea; Cosimi, Reese A.; Reveles, Kelly R.; Evoy, Kirk E. Less Infectious Diseases in Clinical Practice. 26(2):60-65, March 2018. Abstract Abstract In Brief In Brief Favorites PDF Get Content & Permissions Abstract: In Brief: Clostridium difficile infection (CDI) incidence has doubled from 2001 to 2010. Despite appropriate therapy, the likelihood of first recurrence is 10–20%, which subsequently increases to 40–65% after the initial recurrence. Bexlotoxumab is a new monoclonal antibody that provides passive immunity against the virulent toxin B produced by C. difficile during an infection. Bezlotoxumab showed a 10% reduction in recurrent CDI infections compared to placebo when used with standard of care antibiotics.